Raissy Hengameh, Blake Kathryn
Department of Pediatrics, School of Medicine, University of New Mexico , Alburquerque, New Mexico.
Biomedical Research Department, Nemours Children's Clinic , Jacksonville, Florida.
Pediatr Allergy Immunol Pulmonol. 2015 Sep 1;28(3):187-190. doi: 10.1089/ped.2015.0562.
Recently, the United States Food and Drug Administration (FDA) elected not to approve a once-daily inhaled corticosteroid/long-acting β2 agonist combination product in 12-17-year-old patients due to lack of sufficient data, despite approval of previous combination products with similar levels of supporting evidence. As the FDA's stance toward adolescent data is changing, the opportunity to learn about their response to asthma medication has now arisen. A review of the relevant issues pertinent to pharmacotherapy of asthma in the 12-17-year-old population is discussed in this review.